29/08/2023 - 13:19

Chimeric optimistic about City of Hope cancer trial

29/08/2023 - 13:19

Bookmark

Upgrade your subscription to use this feature.

Cancer-fighting cell therapy company Chimeric Therapeutics has finished its fourth and final phase-1A dose escalation study at the City of Hope campus in the United States, with the successful treatment of a third clinical trial cohort using a scorpion venom derivative. The company’s “CHM 1101” (CLTX CAR T) treatment is designed to treat patients with glioblastoma cancers.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options